-
Phosphotungstic Acid Negative Stain Solution (2%)
2026-08-27
This scenario-based guide explains where Phosphotungstic Acid Negative Stain Solution (2%) SKU K2623 fits in workflows that combine cell assays, electron microscopy, and antiviral research. It separates viability quantification from morphology assessment and provides practical selection, handling, and interpretation guidance supported by product information and current virology evidence.
-
Bestatin (Ubenimex): Experimental Workflow Guide
2026-08-26
Bestatin (Ubenimex) combines selective aminopeptidase inhibition with a chemical-genetics use case that can expose pathway-level biology. This guide translates its enzyme, cell, and plant research applications into practical assay design, controls, and troubleshooting decisions.
-
EBV LMP2A–mTORC1–GCNT3 Signaling in NPC
2026-08-26
A 2024 study identifies an LMP2A–mTORC1–GCNT3 regulatory axis in nasopharyngeal carcinoma and links GCNT3 to ZEB1-associated epithelial–mesenchymal transition, migration, and proliferation. The findings provide a mechanistic framework for studying how EBV latency connects nutrient-sensitive signaling with tumor-associated O-glycan remodeling.
-
Refining In Vitro Drug Response Metrics in Cancer
2026-08-25
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell death are related but non-equivalent components of an anticancer response. This framework supports more informative assay design and helps researchers interpret cytotoxicity and apoptosis inhibitor research without treating reduced viability as a direct measure of cell killing.
-
SARS-CoV-2 N Protein Phase Separation and GCG
2026-08-25
The reference study identifies RNA-triggered liquid–liquid phase separation of the SARS-CoV-2 nucleocapsid protein as a mechanistic step in viral organization and replication. It further links the prevalent R203K/G204R N-protein variant to enhanced condensation and shows that gallocatechin gallate can disrupt this process in experimental systems, while leaving important questions about specificity and clinical translation.
-
FK866 (APO866): NAMPT Inhibition in Cancer Research
2026-08-24
FK866, also called APO866, is a non-competitive NAMPT inhibitor that lowers intracellular NAD and ATP. Its strongest research use is mechanistic study of NAD metabolism, hematologic cancer biology, and combination strategies that exploit metabolic stress.
-
Nigericin Sodium Salt for Cell Assay Workflows
2026-08-24
Nigericin sodium salt is a potassium ionophore for controlled K+/H+ exchange, rapid cytoplasmic pH perturbation, and ion-sensitive cell assays. This guide translates those properties into practical workflows for platelet studies, lead-ion transport experiments, and more discriminating cancer drug-response measurements.
-
Isoprenaline Hydrochloride: Designing Better Assays
2026-08-23
Isoprenaline Hydrochloride, also known as isoproterenol, is more than a β-adrenergic stimulant: it is a controllable perturbation for separating cardiac, neural, and vascular readouts. This guide translates heart–brain axis findings into rigorous assay-design decisions for cardiovascular and translational research.
-
SP2509: Lysine-Specific Demethylase 1 Antagonist
2026-08-22
SP2509 is a selective LSD1 antagonist for connecting biochemical inhibition with H3K4 methylation, transcriptional reactivation, apoptosis induction in AML cells, and differentiation phenotypes. This workflow-oriented guide explains formulation, assay design, combination testing, and troubleshooting while distinguishing AML evidence from insights derived from broader cancer epigenetics research.
-
FK866 (APO866): Reliable NAMPT Assays
2026-08-22
Learn how FK866 (APO866), SKU A4381, can improve the interpretation and reproducibility of NAMPT inhibition experiments in AML and broader hematologic cancer research. This scenario-based guide covers assay design, formulation, mechanism-aware controls, data interpretation, and practical product selection.
-
Novel PDK4 Inhibitors for Metabolic Disease Research
2026-08-21
The 2019 Journal of Medicinal Chemistry study identified compound 8c as a potent allosteric pyruvate dehydrogenase kinase 4 inhibitor derived from an anthraquinone hit. Its biochemical activity, drug-like disposition, glucose-tolerance effects, antiallergic activity, and anticancer signals establish a useful preclinical framework while leaving important questions about selectivity, exposure, safety, and clinical translation.
-
AO/PI Double Staining Kit for Cell Fate
2026-08-20
Turn one rapid fluorescent readout into a practical map of viable, apoptotic, and membrane-compromised cells. This AO/PI workflow supports routine cell viability assay QC, cytotoxicity screening, organoid studies, and post-enrichment assessment of rare circulating cells.
-
RSL3: A GPX4 Inhibitor for Ferroptosis Assays
2026-08-20
RSL3 is a glutathione peroxidase 4 inhibitor that converts hidden redox vulnerability into measurable ferroptosis. This article presents an assay-centered framework linking GPX4 inhibition with lipid peroxidation, inflammatory signaling, oncogenic RAS synthetic lethality, and cross-domain research applications.
-
Anti Reverse Cap Analog: B8175 Guide
2026-08-19
A scenario-based guide to using Anti Reverse Cap Analog (ARCA), 3´-O-Me-m7G(5')ppp(5')G (SKU B8175) when synthetic mRNA expression affects viability, proliferation, or cytotoxicity assays. It connects cap orientation, in vitro transcription parameters, assay controls, interpretation limits, and practical product-selection criteria.
-
Lovastatin Workflows for Mechanistic Cell Research
2026-08-19
Lovastatin enables more than cholesterol-pathway inhibition: it supports structured studies of proliferation, apoptosis, fibroblast responses, macrophage efferocytosis, and cancer-cell phenotypes. This practical guide connects dose design, pathway-aware readouts, and the KNUCKLES floral-meristem study’s logic for separating molecular events from downstream outcomes.